Literature DB >> 18029325

Clinical results versus subjective improvement with anterior transposition in cubital tunnel syndrome.

Kamil Cagri Köse1, Sinan Bilgin, Oguz Cebesoy, Levent Altinel, Burak Akan, Dervis Guner, Beyza Doganay, Sinan Adiyaman, Mehmet Demirtas.   

Abstract

This study was conducted to compare the results of anterior transposition methods and to determine the time needed to attain subjective well-being in patients with cubital tunnel syndrome. A total of 49 cases were retrospectively evaluated. Patients were called for follow-up, completed a questionnaire, and were reexamined. They were assigned to one of 3 groups: subcutaneous transposition (SCT), submuscular transposition (SMT), or intramuscular transposition (IMT). The McGowan classification and Wilson-Krout criteria were used for classification and outcomes assessments. Categorical variables were analyzed with the chi2 test, and metric variables by analysis of variance or through Kruskal-Wallis variance analysis. Improvement of at least 1 McGowan grade was observed in 87.63% of patients. The least responsive group was assigned a McGowan grade of III. The most effective procedure for resolving clawing was SMT. Clinical results were excellent in 26 patients (53.06%), good in 12 (24.48%), fair in 4 (8.16%), and poor in 7 (14.28%). At the latest follow-up, overall grip and pinch strength had improved by 23% and 34%, respectively, compared with the contralateral side. Thirty-six patients exhibited an improvement in grip power and 38 in fine dexterity. Complete resolution of numbness was observed in 32 patients, and complete resolution of pain was noted in 30 patients. The preoperative mean visual analog scale score of 6.82 improved to 3.36 postoperatively. Clawing improved in 4 patients and atrophy in 7. The mean time to subjective improvement was shortest in the SMT group and longest in the IMT group. The greatest pain relief was reported in the IMT group and the least in the SMT group. One case with IMT required reoperation because of recompression of the nerve. The most frequent complication in the SMT and IMT groups was muscular tenderness. In conclusion, SCT offers an alternative to other anterior transposition methods because of its simplicity and quicker recovery time, especially in mild to moderate cases.

Entities:  

Mesh:

Year:  2007        PMID: 18029325     DOI: 10.1007/bf02877704

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

1.  Recurrent ulnar nerve entrapment at the elbow: Correlation of surgical findings and 3-Tesla magnetic resonance neurography.

Authors:  Avneesh Chhabra; Vibhor Wadhwa; Rashmi S Thakkar; John A Carrino; A Lee Dellon
Journal:  Can J Plast Surg       Date:  2013

2.  Comparison of anterior subcutaneous and submuscular transposition of ulnar nerve in treatment of cubital tunnel syndrome: A prospective randomized trial.

Authors:  Abolghassem Zarezadeh; Hamidreza Shemshaki; Mohsen Nourbakhsh; Mohammad R Etemadifar; Malihe Moeini; Farhad Mazoochian
Journal:  J Res Med Sci       Date:  2012-08       Impact factor: 1.852

3.  Safety and Outcomes of Different Surgical Techniques for Cubital Tunnel Decompression: A Systematic Review and Network Meta-analysis.

Authors:  Ryckie G Wade; Timothy T Griffiths; Robert Flather; Nicholas E Burr; Mario Teo; Grainne Bourke
Journal:  JAMA Netw Open       Date:  2020-11-02

4.  Subcutaneous vs Submuscular Ulnar Nerve Transposition in Moderate Cubital Tunnel Syndrome.

Authors:  Dhia A K Jaddue; Salwan A Saloo; Arkan S Sayed-Noor
Journal:  Open Orthop J       Date:  2009-08-27

Review 5.  Subcutaneous Versus Submuscular Anterior Transposition of the Ulnar Nerve for Cubital Tunnel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.

Authors:  Chun-Hua Liu; Shi-Qiang Wu; Xiao-Bin Ke; Han-Long Wang; Chang-Xian Chen; Zhan-Long Lai; Zhi-Yong Zhuang; Zhi-Qiang Wu; Qin Lin
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.